Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Bapineuzumab

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    7 result(s) found for: Bapineuzumab. Displaying page 1 of 1.
    EudraCT Number: 2009-012748-17 Sponsor Protocol Number: ELN115727-301 Start Date*: 2010-03-11
    Sponsor Name:Janssen Alzheimer Immunotherapy
    Full Title: A phase 3, multicenter, randomised, double-blind, placebo-controlled, parallel group, efficacy and safety trial of bapineuzumab (AAB-001, ELN115727) in subjects with mild to moderate Alzheimer's di...
    Medical condition: Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-005995-14 Sponsor Protocol Number: 3133K1-3001-WW(B2521002) Start Date*: 2009-05-29
    Sponsor Name:Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola road, Collegeville, PA 19426 USA
    Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disea...
    Medical condition: Alzheimer Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IE (Prematurely Ended) BE (Prematurely Ended) DE (Prematurely Ended) FR (Completed) FI (Prematurely Ended) SE (Prematurely Ended) IT (Prematurely Ended) PT (Prematurely Ended) AT (Prematurely Ended) NL (Prematurely Ended) DK (Prematurely Ended) ES (Prematurely Ended) SK (Completed)
    Trial results: View results
    EudraCT Number: 2007-005994-79 Sponsor Protocol Number: 3133K1-3000-WW Start Date*: 2008-05-13
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development
    Full Title: Ensayo de fase III, multicéntrico, aleatorizado, en doble ciego, controlado con placebo y de grupos paralelos, sobre la eficacia y la seguridad del bapineuzumab (AAB-001, ELN115727) en pacientes co...
    Medical condition: Enfermedad de Alzheimer Alzheimer Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012271 Dementia Alzheimer's type PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) IE (Prematurely Ended) GB (Prematurely Ended) BE (Completed) DE (Prematurely Ended) FR (Completed) FI (Prematurely Ended) SE (Prematurely Ended) IT (Prematurely Ended) SK (Completed) PT (Prematurely Ended) AT (Prematurely Ended) NL (Prematurely Ended) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-002133-20 Sponsor Protocol Number: ELN115727-351 Start Date*: 2011-09-16
    Sponsor Name:Janssen Alzheimer Immunotherapy
    Full Title: A Phase 3 Extension, Multicenter, Double-Blind, Long Term Safety and Tolerability Treatment Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects with Alzheimer's Disease Who Participated in Study...
    Medical condition: Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-015080-13 Sponsor Protocol Number: 3133K1-3003-WW Start Date*: 2010-01-22
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development
    Full Title: A Phase 3 Extension, Multicenter, Long-term Safety and Tolerability Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Alzheimer Disease Who Are Apolipoprotein E ε4 Carriers and Participat...
    Medical condition: Alzheimer Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012271 Dementia Alzheimer's type PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (Prematurely Ended) BE (Prematurely Ended) ES (Prematurely Ended) PT (Prematurely Ended) SK (Prematurely Ended) IT (Prematurely Ended) FI (Prematurely Ended) NL (Prematurely Ended) SE (Prematurely Ended) AT (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-015079-29 Sponsor Protocol Number: 3133K1-3002-WW Start Date*: 2010-01-22
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development
    Full Title: A Phase 3 Extension, Multicenter, Double-blind, Parallel-Group, Long-term Safety and Tolerability Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Alzheimer Disease Who Are Apolipoprotei...
    Medical condition: Alzheimer Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012271 Dementia Alzheimer's type PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (Prematurely Ended) BE (Prematurely Ended) ES (Prematurely Ended) PT (Prematurely Ended) SK (Prematurely Ended) IT (Prematurely Ended) FI (Prematurely Ended) NL (Prematurely Ended) SE (Prematurely Ended) AT (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-004675-35 Sponsor Protocol Number: AAB-001-251 Start Date*: 2007-08-20
    Sponsor Name:Elan Regulatory Holdings Ltd
    Full Title: A Phase II, Multicenter, Open-Label, Long-Term Treatment Study to Determine the Safety, Tolerability and Efficacy of AAB-001 (ELN115727) in Patients with Alzheimer's Disease who Participated in Stu...
    Medical condition: Mild to Moderate Alzheimers Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended) GB (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 15 17:12:31 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA